Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Biosimilars | Current Treatment | Endocrinology | US/EU | 2017

Login to access report north_east
Contact sales account_box

Recent launches of Merck & Co.’s Lusduna (insulin glargine) in Europe, and Eli Lilly/Boehringer Ingelheim’s Basaglar (insulin glargine) in the United States, have expanded the non-innovator sector of the endocrinology market. Uptake of these products, as well as that of competing insulins and human growth hormone biologics including Omnitrope and Genotropin, will depend on the prescribing behavior of endocrinologists. For this reason, it is critical that manufacturers/marketers of insulin and somatropin biosimilars and brands understand which factors influence endocrinologists’ opinions, actions, and expectations. To this end, Decision Resources Group conducted primary market research with endocrinologists in France, Germany, and the United States.

Questions answered:

  • Have endocrinologists received recommendations to use biosimilars?
  • Are endocrinologists switching patients from reference brands to biosimilars?
  • What factors do endocrinologists consider when choosing among competing biosimilars?
  • How are insulin biosimilars and Omnitrope performing, and what are endocrinologists’ expectations for their future uptake?
  • What are the key drivers and barriers to uptake of insulin and somatropin biosimilars?

Key markets covered:

  • France
  • Germany
  • United States

Key companies mentioned:

  • Boehringer Ingelheim
  • Eli Lilly
  • Merck & Co.
  • Novo Nordisk
  • Sanofi

Key drugs mentioned:

  • Apidra
  • Basaglar/Abasaglar
  • Genotropin
  • Humalog
  • Humatrope
  • Lantus
  • Levemir
  • Lusduna Nexvue/Lusduna
  • Norditropin
  • NovoLog/NovoRapid
  • Nutropin
  • Omnitrope
  • Saizen
  • Toujeo
  • Tresiba
Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Amyotrophic Lateral Sclerosis – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Amyotrophic lateral sclerosis (ALS) is a disorder of the central nervous system characterized by motor neuron degeneration. ALS causes progressive weakness and atrophy of the muscles and loss of…
north_east
Report
Kidney Transplant – Current Treatment – Treatment Algorithms: Claims Data Analysis – Kidney Transplant (US)
Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent rejection and maintain the new kidney’s functionality, patients must…
north_east
Report
Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)
Hyperkalemia is a potentially life-threatening condition characterized by a serum potassium concentration that exceeds 5.5 mEq/L. Despite various guidelines, a universally accepted consensus on the…
north_east
Report
Primary Biliary Cholangitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Primary Biliary Cholangitis (US)
Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation and progressive damage to intrahepatic bile ducts, leading to bile buildup, followed by…
north_east
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east